Last reviewed · How we verify
Vorinostat, capecitabine, and cisplatin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Vorinostat, capecitabine, and cisplatin (Vorinostat, capecitabine, and cisplatin) — Asan Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Vorinostat, capecitabine, and cisplatin TARGET | Vorinostat, capecitabine, and cisplatin | Asan Medical Center | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Vorinostat, capecitabine, and cisplatin CI watch — RSS
- Vorinostat, capecitabine, and cisplatin CI watch — Atom
- Vorinostat, capecitabine, and cisplatin CI watch — JSON
- Vorinostat, capecitabine, and cisplatin alone — RSS
Cite this brief
Drug Landscape (2026). Vorinostat, capecitabine, and cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/vorinostat-capecitabine-and-cisplatin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab